COMPUTERISED DESIGNING OF DOXORUBICIN WITH BREAST CANCER CELLS

---

Atıf İçin Kopyala

Sener L., Gunduz S., Şener A., Bicak B., Kokcu Y., Ozel A., ...Daha Fazla

JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI, cilt.82, sa.1, ss.40-46, 2019 (ESCI)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 82 Sayı: 1
• Basım Tarihi: 2019
• Doi Numarası: 10.26650/iuitfd.0005
• Dergi Adı: JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI
• Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
• Sayfa Sayıları: ss.40-46
• İstanbul Üniversitesi Adresli: Evet

Özet

Objective: Breast cancer is the type of cancer that starts in breast cells and has the highest incidence in the world after lung cancer. Doxorubicin is widely used in the treatment of some leukemia and Hodgkin's lymphoma, as well as in the treatment of bladder, breast, stomach, lung, ovary, thyroid, soft tissue sarcoma, multiple myeloma and other cancers. We want to determine the binding interaction of Doxorubicin in the active site of the Galectin-3 with ASN-48, ARG-32, ASN-62 and GLU-72 residues, conformation and docking score energies.